Tuesday, May 19, 2026 7:31:57 PM
Anyway
As of March 31, 2026, the Company had cash and cash equivalents of $917,552. Management has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.
The Company’s current cash balance is insufficient to fund operations. During the three months ended March 31, 2026, the Company incurred significant expenses, primarily related to activities in preparation for potential regulatory approvals by the U.S. Food and Drug Administration and other countries regulatory authorities. The Company expects vendor and related costs associated with these efforts to total approximately $20.0 million and continue into the remainder of 2026.
These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.
You're betting on them getting a priority voucher
Good luck
Kiwi
Recent UNCY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:30:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 08:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:51:50 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 10:30:46 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 11:04:02 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 11:02:10 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 11:00:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 01:11:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:29:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 10:32:02 AM
- Unicycive shares gain as FDA accepts resubmitted OLC NDA • IH Market News • 01/29/2026 03:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/14/2025 10:09:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 02:12:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:39:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2025 11:30:13 AM
- UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit • PR Newswire (US) • 10/14/2025 06:55:00 AM
